Novo Nordisk ® ond glycaemic control and t the CV risk benefits ADA/EASD diabetes treatment guidelines for second-line treatment with established ASCVC or CKD First-line therapy is metformin and lifestyle management. If HbA 1c above target, proceed as below Established ASCVD or CKD NO Without established ASCVD or CKD YES ASCVD predominates GLP-1 with proven CVD benefit * SGLT-2 with proven CVD benefit*, if eGFR adequate EITHER/OR HF OR CKD predominant If HbA 1c above target If further intensification is required or patient is now unable to tolerate GLP-1 and/or SGLT-2, choose agents demonstrating CV safety Sources: Adapted from: Nathan DM, et al. Diabetes Care. 2006; 29: 1963-1972; Nathan DM, et al. 2007;30:753- 759; Nathan DM, et al. Diabetes Care. 2008;31:173-175. ADA. Diabetes Care. 2008; 31:S12-S54. WelChol PI. 1/2008. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Download PDF file